CLSTN1 Protein, Human (HEK293, His)

The CLSTN1 protein acts as a postsynaptic adhesion molecule and promotes excitatory and inhibitory synapse formation by binding to presynaptic neurotoxins.It acts as a cell adhesion molecule on the postsynaptic membrane and forms an association with neurotoxin-α on the presynaptic membrane.CLSTN1 Protein, Human (HEK293, His) is the recombinant human-derived CLSTN1 protein, expressed by HEK293 , with C-His labeled tag.

CLSTN1 Protein functions as a postsynaptic adhesion molecule, fostering both excitatory and inhibitory synapse formation by binding to presynaptic neurexins. In the realm of synapse development, CLSTN1 acts as a cell adhesion molecule at the postsynaptic membrane, forming associations with neurexin-alpha at the presynaptic membrane. Beyond its role in synapse formation, CLSTN1 serves as a molecular adapter, participating in axonal anterograde transport by promoting KLC1 association with vesicles. Moreover, it engages in complex formation with APBA2 and APP, stabilizing APP metabolism and enhancing APBA2-mediated suppression of beta-APP40 secretion, contributing to the regulation of intracellular APP maturation. As the intracellular fragment AlcICD, CLSTN1 plays a role in suppressing APBB1-dependent transactivation stimulated by APP C-terminal intracellular fragment (AICD), potentially by competing with AICD for APBB1-binding. These diverse functions underscore the versatile role of CLSTN1 in orchestrating molecular events critical for synapse development and intracellular signaling.

Human

HEK293

C-10*His

O94985-1 (A29-T859)

22883  [NCBI]

ARVNKHKPWLEPTYHGIVTENDNTVLLDPPLIALDKDAPLRFAESFEVTVTKEGEICGFKIHGQNVPFDAVVVDKSTGEGVIRSKEKLDCELQKDYSFTIQAYDCGKGPDGTNVKKSHKATVHIQVNDVNEYAPVFKEKSYKATVIEGKQYDSILRVEAVDADCSPQFSQICSYEIITPDVPFTVDKDGYIKNTEKLNYGKEHQYKLTVTAYDCGKKRATEDVLVKISIKPTCTPGWQGWNNRIEYEPGTGALAVFPNIHLETCDEPVASVQATVELETSHIGKGCDRDTYSEKSLHRLCGAAAGTAELLPSPSGSLNWTMGLPTDNGHDSDQVFEFNGTQAVRIPDGVVSVSPKEPFTISVWMRHGPFGRKKETILCSSDKTDMNRHHYSLYVHGCRLIFLFRQDPSEEKKYRPAEFHWKLNQVCDEEWHHYVLNVEFPSVTLYVDGTSHEPFSVTEDYPLHPSKIETQLVVGACWQEFSGVENDNETEPVTVASAGGDLHMTQFFRGNLAGLTLRSGKLADKKVIDCLYTCKEGLDLQVLEDSGRGVQIQAHPSQLVLTLEGEDLGELDKAMQHISYLNSRQFPTPGIRRLKITSTIKCFNEATCISVPPVDGYVMVLQPEEPKISLSGVHHFARAASEFESSEGVFLFPELRIISTITREVEPEGDGAEDPTVQESLVSEEIVHDLDTCEVTVEGEELNHEQESLEVDMARLQQKGIEVSSSELGMTFTGVDTMASYEEVLHLLRYRNWHARSLLDRKFKLICSELNGRYISNEFKVEVNVIHTANPMEHANHMAAQPQFVHPEHRSFVDLSGHNLANPHPFAVVPST

Approximately 95-130 kDa due to the glycosylation

• 
  Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.